To better assess the potential therapeutic value of Torin-2 in B-pre ALL, we analyzed its synergistic potential with MK-2206, an orally active, allosteric Akt inhibitor, which is currently tested in phase II clinical trials. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.